CL-SBP-101-04

 The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

Acronym:

CL-SBP-101-04

ACTRN/NCT /ethics:

NCT05254171

Scientific title:

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Sponsor / Cooperative group:

Panbela Therapeutics, Inc.